Detalhe da pesquisa
1.
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
Clin Infect Dis
; 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38305378
2.
Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.
Blood
; 129(9): 1155-1165, 2017 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28031181
3.
The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC).
Eur J Haematol
; 2018 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30030853
4.
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.
Proc Natl Acad Sci U S A
; 112(9): E966-72, 2015 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-25730880
5.
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
N Engl J Med
; 370(24): 2286-94, 2014 Jun 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-24869598
6.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
N Engl J Med
; 369(6): 507-16, 2013 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23782157
7.
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
N Engl J Med
; 369(1): 32-42, 2013 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-23782158
8.
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
Blood
; 123(8): 1207-13, 2014 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24311722
9.
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
Blood
; 122(14): 2412-24, 2013 Oct 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-23940282
10.
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Blood
; 122(15): 2539-49, 2013 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23886836
11.
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
Lancet Oncol
; 15(1): 48-58, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24332241
12.
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
Blood
; 119(11): 2590-4, 2012 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22279054
13.
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Blood
; 120(9): 1877-87, 2012 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-22689860
14.
JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.
J Immunol
; 183(3): 2183-92, 2009 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19596999
15.
Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction.
Hematology
; 25(1): 112-117, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32131714
16.
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Mol Cancer Ther
; 16(7): 1246-1256, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28428442
17.
Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
Mol Cancer Ther
; 15(12): 2835-2844, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27678331
18.
The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.
Am J Cancer Res
; 6(11): 2489-2501, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27904766
19.
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.
Cancer Discov
; 6(3): 270-85, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26715645
20.
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Clin Cancer Res
; 22(7): 1572-82, 2016 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26660519